Financial Performance - Total revenue increased by 19% from USD 1382 million to USD 1640 million[39] - Operating profit increased by 56% from USD 352 million to USD 548 million[39] - Recurring revenue grew by 27%[38] - Combined commercialized medicines sales increased by 60% from USD 181 million to USD 289 million[23] - Cash reserves stand at USD 29 billion[12] Product Performance - EPKINLY net sales increased by 74% to USD 211 million[27] - TIVDAK net sales increased by 30% to USD 78 million[32] - Rina-S® showed a confirmed ORR of 500% in endometrial cancer patients[17] Pipeline Development - EPCORE® FL-1 clinical trial met dual primary endpoints of ORR and PFS, reducing the risk of disease progression or death by 79%[14] - sBLA for EPKINLY® in 2L FL accepted with a PDUFA date of November 30, 2025[13] Guidance - Revenue guidance improved to USD 3500-3700 million, representing a 15% year-over-year growth[41] - Operating profit guidance improved to USD 1055-1405 million, representing a 26% year-over-year growth[41]

Financial Performance - Second Quarter 2025 - Total revenue increased to $66 million from $64 million, a 3% increase year-over-year[2,4] - Verification and certification revenue increased to $533 million from $525 million[2,6] - Product sales increased to $964,000 from $819,000[2,6] - Net income increased to $562,000, or $011 per diluted share, from $489,000, or $009 per diluted share, a 15% increase[2,3,7] Financial Performance - Six Months 2025 - Total revenue decreased to $118 million from $120 million[2,8] - Verification and certification services was $95 million vs $97 million[2,12] - Product revenue was $17 million vs $16 million[2,12] - Net income decreased to $593,000, or $011 per diluted share, from $667,000, or $012 per diluted share[2,9] Strategic Actions - The company sold its 10% interest in Progressive Beef for $18 million in cash and the return of 12,585 shares of WFCF common stock[1,6] - The company bought back 24,481 shares in the second quarter and 55,826 shares in the first six months of 2025[2,6,7,10]

Financial Performance - Reported Q2-2025 adjusted EPS of $0.89 and YTD-2025 adjusted EPS of $2.34[12] - Affirmed FY-2025 adjusted EPS guidance range of $4.30 - $4.70[12] - Affirmed FY-2026 EPS guidance range of $4.80 - $5.30[12] - Affirmed guidance at high-end or above projected EPS CAGR of 7% - 9% for 2025 through 2029[12] - Oncor invested $3 billion of CapEx, supporting premise count increase of 20,000[16] Strategic Initiatives - Invested over $5 billion of CapEx in 1H-2025[11] - Executed an effort to save $300 million by phasing out certain non-economic regulatory programs in California[11] - Initiated Ecogas sale process[11] - Extended ROFO process with existing limited partners and signed non-binding letter of intent with KKR[11] Operational Excellence and Infrastructure Development - Hardened 100% of SDGE's transmission system located in Tier 3 HFTD, with 100% of all HFTD transmission expected in 2028[11] - Safely completed 1,000th LNG cargo from Cameron LNG Phase 1 since start of operations[11] - SDGE awarded estimated $600 million of projects in finalized CAISO 2024 – 2025 Transmission Plan[16]

Company Overview - IIPR has a total committed/invested capital of $2.5 billion[10] - The company owns 108 properties with a total rentable square footage of 9 million[10] - IIPR's portfolio spans across 19 US states[10] - The Q2 2025 annualized dividend is $7.60[10] - Q2 2025 total revenue reached $62.9 million[10] - The weighted average lease length is 13.1 years[10] Financial Strength - IIPR's debt to total gross assets is 11%[31] - The debt service coverage ratio is 15x[32] - The company has over $192 million in available liquidity[34] Market Position and Growth - The regulated cannabis market is estimated to grow at a 7% CAGR over the next 5 years[17] - US legal cannabis sales are projected to grow from an estimated $31 billion in 2024 to $44 billion by 2029[20]

Financial Performance - Sales increased to $4987 million, a 119% year-over-year increase compared to Q2 2024, and a 46% sequential increase from Q1 2025[7] - Organic sales grew 123% year-over-year and 64% sequentially[7] - Net income for Q2 2025 was $236 million, compared to $167 million for Q2 2024 and $206 million for Q1 2025[7] - Adjusted EBITDA for Q2 2025 was $573 million compared to $482 million for Q2 2024 and $525 million for Q1 2025[7] - Adjusted EBITDA margin was 115%, 108%, and 110%, respectively[7] Cash Flow - Net cash provided by operating activities was $186 million for Q2 2025[19] - Free cash flow was $83 million for Q2 2025[19] Strategic Initiatives - The company closed one acquisition during Q2 2025 and one subsequent to quarter end[7] - The company has a flexible share repurchase program for opportunistic buybacks[24]

Financial Performance - Adjusted earnings were $155.4 million, or $0.43 per share[11] - Record mine operating earnings reached $273.3 million[11] - Record free cash flow amounted to $233.0 million[11] - The company maintains a strong financial position with $1.9 billion in total available liquidity[11] - Revenue for Q2 2025 was $811.9 million, and for H1 2025 it was $1,585.1 million[13] Production and Costs - Silver production reached 5.1 million ounces, and gold production was 178.7 thousand ounces[11] - Silver Segment AISC (All-in Sustaining Costs) was $19.69 per ounce, while Gold Segment AISC was $1,611 per ounce[11] Liquidity and Debt - Cash and short-term investments totaled $1,109 million[45] - Total debt was $820.7 million, primarily related to senior notes[45] 2025 Operating Outlook - The company is maintaining its 2025 operating outlook[11] - The company anticipates silver production between 20.00 and 21.00 million ounces for the full year 2025[46] - The company anticipates gold production between 735 and 800 thousand ounces for the full year 2025[46]

Financial Performance - Cheniere's Net Income increased to $1626 million in 2Q 2025, compared to $880 million in 2Q 2024[12] - Consolidated Adjusted EBITDA increased to $1416 million in 2Q 2025, compared to $1322 million in 2Q 2024[12] - Distributable Cash Flow increased to approximately $920 million in 2Q 2025, compared to approximately $700 million in 2Q 2024[12] - Approximately $13 billion was deployed in 2Q 2025, including ~$306 million for repurchasing ~14 million shares[16] Guidance and Outlook - The company is raising and tightening its full-year 2025 Consolidated Adjusted EBITDA guidance to $66 billion - $70 billion, from a prior range of $65 billion - $70 billion[13] - The company is raising and tightening its full-year 2025 Distributable Cash Flow guidance to $44 billion - $48 billion, from a prior range of $41 billion - $46 billion[13] - Cheniere expects to have >$25 billion of available cash through 2030, aiming to reach >$25/share of run-rate Distributable Cash Flow[16] Operational Highlights - Cheniere loaded 550 TBtu of LNG and exported 154 cargoes in 2Q 2025[16] - CCL Stage 3 Train 2 achieved Substantial Completion in August[16] - CCL Stage 3 total project completion was 867% as of June 30, 2025[21] Commercial Progress - Cheniere signed a commercial agreement for ~10 MTPA FOB from 2029 through 2050[14] - Cheniere signed a commercial agreement for ~085 MTPA IPM for 15 years beginning in ~2030[15]

FY25 Performance Highlights - Parker Hannifin achieved record sales of $199 billion, with organic sales growth of 1%[6] - The company's adjusted segment operating margin reached a record 261%, a 120 basis points increase[6] - Adjusted EBITDA margin also hit a record of 264%, up by 80 basis points[6] - Adjusted EPS growth was 7%[6] - Cash flow from operations reached a record $38 billion, a 12% increase[6] Q4 FY25 Financial Summary - Reported sales were $5243 million, a 1% increase compared to Q4 FY24[29] - Segment operating margin was 239%, adjusted to 269%, a 160 basis points increase year-over-year[29] - Net income was $923 million, adjusted to $992 million, a 12% increase[29] - EPS was $715, adjusted to $769, a 14% increase[29] FY26 Guidance - The company forecasts organic sales growth of approximately 3%[39] - Adjusted EPS is projected to be between $2840 and $2940[41] - Free cash flow is expected to be between $30 billion and $34 billion[41]

Q2 2025 Key Financial Highlights - Revenue grew by 15% year-over-year in Q2[7] - Net income increased by 120% year-over-year for Q2[7] - Adjusted EBITDA increased by 12% year-over-year for Q2, reaching 22.7% of revenue, aligning with the full-year outlook[7] - The company repurchased 270,061 common shares for $1.8 million, at an average price of $6.79 per share[7] Operational Performance - Vent patient growth was robust, with an 11% year-over-year increase in Q2 and a 3% sequential increase from Q1[7] - Sleep therapy patients increased significantly, up 51% year-over-year and 15% sequentially in Q2; new sleep patient starts were up 72% year-over-year, and sleep resupply patient count was up 25% year-over-year and 10% sequentially[7] Financial Position and Strategy - The company completed the strategic acquisition of Lehan's Medical Equipment on July 1, 2025, expected to contribute starting in Q3[6] - As of June 30, 2025, the company had $55 million in unfunded commitments available under its existing credit facilities[19] - The company maintains a healthy balance sheet with no net debt as of June 30, 2025[19] 2025 Guidance - Net revenue is projected to be between $271 million and $277 million, an increase from the previous guidance of $256 million to $265 million[22] - Adjusted EBITDA is expected to be between $59 million and $62 million, representing 22% of net revenue, an increase from the previous guidance of $55 million to $58 million[22]

Financial Performance - Consolidated revenue increased by 15% year-over-year to $76.4 million[9, 12] - Service segment revenue grew by 12% to $49.1 million[9, 12] - Distribution segment revenue increased by 19% to $27.3 million[9, 12] - Consolidated gross profit increased by 14% to $25.8 million[15, 16] - Adjusted EBITDA increased by 15% to $11.8 million[9, 21, 23] - Net income decreased by 26% to $3.3 million[9, 19] Segment Performance - Service segment gross profit increased by 9% to $16.2 million[9, 15, 16] - Distribution segment gross profit increased by 24% to $9.6 million, with gross margin expansion of 130bps to 35.2%[9, 15, 16] - Distribution adjusted EBITDA increased by 49% to $4.8 million[21, 23] Strategic Initiatives - Transcat acquired Essco Calibration Laboratory for $84 million in cash[10] - A new 5-year $150 million syndicated secured credit facility was established[9, 10, 28]